TRAC and leukemia: eSHS6-CAR T cells maintained robust anti-tumor activity even after multiple leukemia rechallenges and demonstrated proliferation, persistence, and tumor clearance similar to T-Cell Receptor Alpha Constant (TRAC)-CAR T cells [44].